Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Houston Methodist Neal Cancer Center, Houston, TX, 77030, USA.
Biomed Microdevices. 2024 Feb 7;26(1):16. doi: 10.1007/s10544-024-00698-y.
Non-coding RNA (ncRNA)-based therapeutics that induce RNA interference (RNAi), such as microRNAs (miRNAs), have drawn considerable attention as a novel class of targeted cancer therapeutics because of their capacity to specifically target oncogenes/protooncogenes that regulate key signaling pathways involved in carcinogenesis, tumor growth and progression, metastasis, cell survival, proliferation, angiogenesis, and drug resistance. However, clinical translation of miRNA-based therapeutics, in particular, has been challenging due to the ineffective delivery of ncRNA molecules into tumors and their uptake into cancer cells. Recently, superparamagnetic iron oxide-based nanoparticles (SPIONs) have emerged as highly effective and efficient for the delivery of therapeutic RNAs to malignant tissues, as well as theranostic (therapy and diagnostic) applications, due to their excellent biocompatibility, magnetic responsiveness, broad functional surface modification, safety, and biodistribution profiles. This review highlights recent advances in the use of SPIONs for the delivery of ncRNA-based therapeutics with an emphasis on their synthesis and coating strategies. Moreover, the advantages and current limitations of SPIONs and their future perspectives are discussed.
基于非编码 RNA(ncRNA)的治疗方法,如 microRNAs(miRNAs),通过诱导 RNA 干扰(RNAi),引起了人们的极大关注,成为一类新型的靶向癌症治疗方法,因为它们能够特异性地靶向调节致癌基因/原癌基因,这些基因参与肿瘤发生、肿瘤生长和进展、转移、细胞存活、增殖、血管生成和耐药性等关键信号通路。然而,由于 ncRNA 分子在肿瘤中的有效传递及其在癌细胞中的摄取效率低下,miRNA 治疗方法的临床转化一直具有挑战性。最近,超顺磁性氧化铁纳米粒子(SPIONs)由于其优异的生物相容性、磁响应性、广泛的功能表面修饰、安全性和生物分布特性,已成为向恶性组织以及治疗诊断(治疗和诊断)应用中递送治疗性 RNA 的高效方法。本文重点介绍了 SPIONs 在递送 ncRNA 治疗方法方面的最新进展,强调了其合成和涂层策略。此外,还讨论了 SPIONs 的优势、当前的局限性及其未来展望。
Biomed Microdevices. 2024-2-7
Acc Chem Res. 2019-5-28
Acta Biomater. 2020-1-15
Acc Chem Res. 2011-4-29
Expert Opin Drug Deliv. 2014-5-29
Adv Drug Deliv Rev. 2022-3
J Transl Med. 2025-4-16
Molecules. 2024-5-1
Tzu Chi Med J. 2022-7-27
Nanomaterials (Basel). 2022-9-24
Mol Cancer. 2022-8-4
J Pharmacol Exp Ther. 2023-1
Pharmaceutics. 2022-1-16